Waygesic SP Tablet is a combination analgesic and anti-inflammatory medication containing Aceclofenac 100 mg, Paracetamol 325 mg, and Serratiopeptidase 15 mg. Aceclofenac, a non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase enzymes, thereby reducing prostaglandin synthesis and alleviating pain and inflammation. Paracetamol acts centrally to provide effective analgesia and antipyresis by inhibiting prostaglandin synthesis in the central nervous system. Serratiopeptidase, a proteolytic enzyme, facilitates the breakdown of inflammatory mediators and promotes the resolution of edema and tissue inflammation. This combination is indicated for the management of acute and chronic musculoskeletal pain, osteoarthritis, rheumatoid arthritis, postoperative pain, and soft tissue injuries. Waygesic SP Tablet offers synergistic effects by targeting multiple pathways involved in pain and inflammation, resulting in enhanced efficacy and improved patient outcomes. It is generally well-tolerated; however, caution is advised in patients with gastrointestinal ulcers, renal or hepatic impairment, and hypersensitivity to NSAIDs. The medication should be used under medical supervision, adhering to prescribed dosages to minimize adverse effects such as gastrointestinal discomfort, allergic reactions, or altered liver function. Waygesic SP Tablet provides a comprehensive approach to pain management by combining anti-inflammatory, analgesic, and proteolytic actions in a single formulation.